AstraZeneca Income Taxes 2010-2024 | AZN

AstraZeneca annual/quarterly income taxes history and growth rate from 2010 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.
  • AstraZeneca income taxes for the quarter ending June 30, 2024 were $0.469B, a 75% increase year-over-year.
  • AstraZeneca income taxes for the twelve months ending June 30, 2024 were $1.301B, a 1202.54% decline year-over-year.
  • AstraZeneca annual income taxes for 2023 were $0.938B, a 218.43% decline from 2022.
  • AstraZeneca annual income taxes for 2022 were $-0.792B, a 108.42% increase from 2021.
  • AstraZeneca annual income taxes for 2021 were $-0.38B, a 149.22% decline from 2020.
AstraZeneca Annual Income Taxes
(Millions of US $)
2023 $938
2022 $-792
2021 $-380
2020 $772
2019 $321
2018 $-57
2017 $-641
2016 $146
2015 $243
2014 $11
2013 $696
2012 $1,376
2011 $2,333
2010 $2,896
2009 $3,263
AstraZeneca Quarterly Income Taxes
(Millions of US $)
2024-06-30 $469
2024-03-31 $620
2023-12-31 $-62
2023-09-30 $274
2023-06-30 $268
2023-03-31 $458
2022-12-31 $-124
2022-09-30 $-720
2022-06-30 $-113
2022-03-31 $165
2021-12-31 $-290
2021-09-30 $-350
2021-06-30 $214
2021-03-31 $46
2020-12-31 $162
2020-09-30 $202
2020-06-30 $223
2020-03-31 $185
2019-12-31 $-37
2019-09-30 $129
2019-06-30 $34
2019-03-31 $195
2018-12-31 $-279
2018-09-30 $71
2018-06-30 $93
2018-03-31 $58
2017-12-31 $-854
2017-09-30 $97
2017-06-30 $46
2017-03-31 $70
2016-12-31 $366
2016-09-30 $-319
2016-06-30 $1
2016-03-31 $98
2015-12-31 $-6
2015-09-30 $161
2015-06-30 $-38
2015-03-31 $126
2014-12-31 $-259
2014-09-30 $69
2014-06-30 $69
2014-03-31 $132
2013-12-31 $-195
2013-09-30 $344
2013-06-30 $255
2013-03-31 $292
2012-12-31 $316
2012-09-30 $511
2012-06-30 $141
2012-03-31 $408
2011-12-31 $541
2011-09-30 $684
2011-06-30 $735
2011-03-31 $373
2010-12-31 $651
2010-09-30 $704
2010-06-30 $801
2010-03-31 $740
2009-12-31 $602
2009-09-30 $911
2009-06-30 $891
2009-03-31 $859
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $202.127B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $777.357B 80.52
Novo Nordisk (NVO) Denmark $480.435B 34.65
Johnson & Johnson (JNJ) United States $367.500B 14.91
AbbVie (ABBV) United States $302.340B 15.91
Merck (MRK) United States $249.371B 16.57
Novartis AG (NVS) Switzerland $214.456B 14.26
Pfizer (PFE) United States $148.418B 10.15
Sanofi (SNY) $127.247B 11.53
Innoviva (INVA) United States $1.271B 10.58